Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703749 | 0.84 | LMNA (0.41) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL10499586 | 0.76 | LMNA (0.42) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL13098251 | 0.76 | LMNA (0.42) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL15257437 | 0.73 | LMNA (0.39) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL15800950 | 0.73 | LMNA (0.39) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL136589 | 0.72 | — | — | |
| SCHEMBL11768933 | 0.71 | LMNA (0.47) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL72471 | 0.71 | LMNA (0.62) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL229792 | 0.71 | TSHR (0.50) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 | |
| Chloromethane SCHEMBL28151447 | 0.70 | LMNA (0.50) | LMNATSHRSMN1; SMN2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240222629-A1 | SECONDARY BATTERY AND MANUFACTURING METHOD THEREOF | SEMICONDUCTOR ENERGY LAB (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20210104744-A1 | SECONDARY BATTERY AND MANUFACTURING METHOD THEREOF | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| US-20180076489-A1 | ELECTRODE AND POWER STORAGE DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180019462-A1 | Graphene Compound, Method for Forming Graphene Compound, and Power Storage Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076489-A1 | ELECTRODE AND POWER STORAGE DEVICE | SELENOI, SOD1, L1CAM | LMNA 585/4885TSHR 4737/4885SMN1; SMN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.